Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

ambrisentan MeSH Supplementary Concept Data 2025


MeSH Supplementary
ambrisentan
Unique ID
C467894
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C467894
Entry Term(s)
(+)-(2S)-2-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid
(+)-ambrisentan
(+-)-ambrisentan
(-)-ambrisentan
(R)-ambrisentan
(S)-ambrisentan
BSF 208075
BSF-208075
BSF208075
GSK 1325760
GSK 1325760A
GSK-1325760
GSK-1325760A
GSK1325760
GSK1325760A
LU 208075
LU-208075
LU208075
Letairis
Volibris
ambrisentan, (+-)-
ambrisentan, (-)-
ambrisentan, (R)-
Pharm Action
Antihypertensive Agents
Registry Numbers
HW6NV07QEC
0
7B43003091
Q1BX7HE63A
Related Numbers
177036-94-1
7B43003091
Q1BX7HE63A
Heading Mapped to
*Phenylpropionates
*Pyridazines
Frequency
285
Note
an ET(A) receptor antagonist and antihypertensive agent; studied for use in pulmonary arterial hypertension
Source
Clin Sci (Lond) 2002 Aug;103 Suppl 48:408S-413S
Indexing Information
Hypertension, Pulmonary
Date of Entry
2002/11/15
Revision Date
2021/07/06
ambrisentan Preferred
BSF 208075 Narrower
LU 208075 Narrower
Letairis Narrower
ambrisentan, (+-)- Broader
ambrisentan, (-)- Narrower
GSK-1325760 Narrower
Volibris Narrower
page delivered in 0.005s